Clinical Trial Update: Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy [Phase 1]

View source ↗

Summary

Phase 1 clinical study of CMP-001 in combination with pembrolizumab or as monotherapy for melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• CMP-001
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Melanoma | Phase 1 | Status: COMPLETED